Notably, secondary liver malignancies and concurrent exemestane use were associated with an increased risk of hepatitis, while the absence of anti-HBs antibodies showed a trend, though not statistically significant, toward increased HBVr risk, which may be due to small sample size and missing antiHBs titer data.
← all excerpts
Hepatitis and Hepatitis B Virus Reactivation in Everolimus-Treated Solid Tumor Patients: A Focus on HBV-Endemic Areas.
1
—
—